Procopio G - Search Results

1

Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study).

Schmidinger M, Bamias A, Procopio G, Hawkins R, Sanchez AR, Vázquez S, Srihari N, Kalofonos H, Bono P, Pisal CB, Hirschberg Y, Dezzani L, Ahmad Q, Jonasch E; PRINCIPAL Study Group. Schmidinger M, et al. Among authors: procopio g. Oncologist. 2019 Apr;24(4):491-497. doi: 10.1634/theoncologist.2018-0787. Epub 2019 Mar 13. Oncologist. 2019. PMID: 30867244 Free PMC article.

2

Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma.

Procopio G, Verzoni E, Gevorgyan A, Mancin M, Pusceddu S, Catena L, Platania M, Guadalupi V, Martinetti A, Bajetta E. Procopio G, et al. Oncology. 2007;73(3-4):204-9. doi: 10.1159/000127387. Epub 2008 Apr 16. Oncology. 2007. PMID: 18418013

3

Feasibility and activity for sequencing targeted therapies for the treatment of advanced renal cell carcinoma.

Procopio G, Verzoni E, Bajetta E. Procopio G, et al. Med Oncol. 2010 Dec;27(4):1267-8. doi: 10.1007/s12032-009-9371-0. Epub 2009 Dec 2. Med Oncol. 2010. PMID: 19957113 No abstract available.

4

Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial.

Procopio G, Verzoni E, Bracarda S, Ricci S, Sacco C, Ridolfi L, Porta C, Miceli R, Zilembo N, Bajetta E. Procopio G, et al. Br J Cancer. 2011 Apr 12;104(8):1256-61. doi: 10.1038/bjc.2011.103. Epub 2011 Mar 29. Br J Cancer. 2011. PMID: 21448165 Free PMC article. Clinical Trial.

5

Targeted therapies used sequentially in metastatic renal cell cancer: overall results from a large experience.

Procopio G, Verzoni E, Iacovelli R, Guadalupi V, Gelsomino F, Buzzoni R. Procopio G, et al. Expert Rev Anticancer Ther. 2011 Nov;11(11):1631-40. doi: 10.1586/era.11.154. Expert Rev Anticancer Ther. 2011. PMID: 22050012 Review.

6

Role of sorafenib in renal cell carcinoma: focus on elderly patients.

Procopio G. Procopio G. Expert Rev Anticancer Ther. 2011 Nov;11(11):1689-92. doi: 10.1586/era.11.153. Expert Rev Anticancer Ther. 2011. PMID: 22050017

7

Management of advanced genitourinary tumors.

Pietrantonio F, Biondani P, Verzoni E, Procopio G. Pietrantonio F, et al. Among authors: procopio g. Tumori. 2012 Mar-Apr;98(2):264-6. doi: 10.1177/030089161209800214. Tumori. 2012. PMID: 22677995

8

Prognostic factors for survival in patients with metastatic renal cell carcinoma treated with targeted therapies.

Procopio G, Verzoni E, Iacovelli R, Biasoni D, Testa I, Porcu L, De Braud F. Procopio G, et al. Br J Cancer. 2012 Oct 9;107(8):1227-32. doi: 10.1038/bjc.2012.327. Epub 2012 Sep 11. Br J Cancer. 2012. PMID: 22968651 Free PMC article.

9

Optimizing further treatment choices in short- and long-term responders to first-line therapy for patients with advanced renal cell carcinoma.

Procopio G, Sabbatini R, Porta C, Verzoni E, Galligioni E, Ortega C. Procopio G, et al. Expert Rev Anticancer Ther. 2012 Aug;12(8):1089-96. doi: 10.1586/era.12.76. Expert Rev Anticancer Ther. 2012. PMID: 23030227 Review.

10

Experience with sorafenib in the treatment of advanced renal cell carcinoma.

Procopio G, Verzoni E, Testa I, Nicolai N, Salvioni R, Debraud F. Procopio G, et al. Ther Adv Urol. 2012 Dec;4(6):303-13. doi: 10.1177/1756287212457216. Ther Adv Urol. 2012. PMID: 23205057 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

356 results

Search Page